The experience of L-arginine using in placental insufficiency

Safarova, S. S.; Aliyeva, E.M.; Abbasova, F.Yu.; Mirzoyeva, Kh.M.

doi:10.32902/2663-0338-2020-3.1-56

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies suggest the possibility of effective and safe use of the properties of L-arginine, as a precursor of NO, in clinical practice for the treatment of gestational hypertension [6,11,14]. Unlike other researchers, we have used a solution for treatment, which in addition to arginine hydrochloride contains levocarnitine, which enhances the clinical effects of arginine.…”

Section: Discussionmentioning

confidence: 99%

Optimization of pharmacotherapy of gestational hypertension

Vaskiv¹,

Григоренко²,

Horbatiuk³

et al. 2022

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. Hypertension in pregnant women disimprove the placental function, impairs fetal development and has an adverse effect on the condition of a woman. Usually dopegyt is used to treat gestational hypertension. However, it reduces the microcirculation of blood in the placenta, causing or increasing pre-existing placental dysfunction. Therefore, the aim of the research is to optimize the method of gestational hypertension pharmacotherapy in pregnant women with a set of infusion drugs including pentoxifylline, arginine hydrochloride with levocarnitine and reosorbilact to prevent fetoplacental dysfunction and perinatal pathology in this case. We examined 73 pregnant women, among whom we distinguished 3 groups: first group (n = 30) - pregnant women with GH, who, along with the basic therapy with dopegyt received a complex of infusion solutions (pentoxifylline, a solution containing arginine hydrochloride and levocarnitine, drug reosorbilact); second group (n=20) - patients with gestational hypertension who received only basic therapy with dopegyt; control group (n=23) - women with physiological pregnancy. Studies of the clinical effectiveness of the proposed treatment were evaluated by cases of prevention of perinatal pathology (intrauterine growth restriction of the fetus (IUGR), premature birth, etc.) and the results of clinical, laboratory and instrumental research methods. Criteria for inclusion in the study were: the presence of blood pressure ≥150/100 mm Hg, dopegyt, gestational age from 28 to 36 weeks, singleton pregnancy. Examination of pregnant women was performed using standard clinical, laboratory and instrumental (Doppler ultrasounds) research methods. The analysis of the obtained data was performed using the program “STATISTICA 5.5”. Established that in patients who received our treatment regimen, there was a significant reduction in the development of placental dysfunction (OR 0.30, 95 % CI [0.12-0.74], p=0.009), fetal IUGR (OR 0.33, 95 % CI [0.12-0.96], p=0.042), acute fetal distress (OR 0.25, 95 % CI [0.075-0.83], p=0.02), weakness of childbirth (OR 0,19, 95 % CI [0.04-0.82], p=0.03), reducing the risk of perinatal CNS damage (OR 0.22, 95 % CI [0.05-0.99], p=0.049 ) and reducing the risk of cephalohematoma (OR 0.25, 95 % CI [0.075-0.83], p=0.024).

show abstract

Section: Discussionmentioning

confidence: 99%

Optimization of pharmacotherapy of gestational hypertension

Vaskiv¹,

Григоренко²,

Horbatiuk³

et al. 2022

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

show abstract

Modern approach to infusion therapy of pregnant women with gestational hypertension

et al. 2023

View full text Add to dashboard Cite

To date, there are no effective treatment for placental dysfunction in pregnant women with gestational hypertension. Therefore, the purpose of our study was to investigate the clinical efficacy of proposed method of infusion therapy for pregnant women with gestational hypertension, which included a complex of drugs: pentoxifylline, arginine hydrochloride with levocarnitine and rheosorbilact. We observed 73 pregnant women with single fetation, starting from 28 weeks of gestation, who were observed before and during childbirth, and in the postpartum period by the time of discharge from the hospital. All examined women were divided into 3 groups. The first group included 30 pregnant women with gestational hypertension, who received (along with the basic therapy of methyldopa drugs) a complex of infusion solutions: pentoxifylline 0.05% – 100 ml; solution containing arginine hydrochloride 4.2% and levocarnitine 2.0% – 100 ml; reosorbilact preparation – 100 ml. The infusion was carried out once a day in the specified sequence for 10 days. The second group included 20 patients with gestational hypertension on basic therapy with methuldopa only. The control group included 23 women with physiological pregnancy. The data of our study show that in patients receiving the proposed infusion therapy there was a significant decrease in the development of placental dysfunction by 38.3%, the threat of premature birth – by 18.3% and fetal distress – by 30.0%, premature rupture of the membranes – by 35.0%, weakness of labor – by 28.3%, a decrease in the risk of perinatal central nervous system damage – by 33.3% and the frequency of cephalohematomas – by 30.0% compared with women who received only antihypertensive therapy.

show abstract

The experience of L-arginine using in placental insufficiency

Cited by 2 publications

References 0 publications

Optimization of pharmacotherapy of gestational hypertension

Optimization of pharmacotherapy of gestational hypertension

Modern approach to infusion therapy of pregnant women with gestational hypertension

Contact Info

Product

Resources

About